A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US
Our CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.
- Our CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.
- CytoMed holds an exclusive, worldwide license, for use on immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
- The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive γδ NKT cells for cancer treatments.
- A patent for this proprietary technology has already been granted in Japan and this asset is under preclinical development.